# EDGAR Filing Document

**Accession Number:** 0001827401
**File Stem:** 0001062993-26-000098
**Filing Date:** 2026-1
**Character Count:** 4102
**Document Hash:** f98ae9e07788fb4d70a901e21230bc14
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-26-000098.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001062993-26-000098

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 36

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-289851
- **FILM NUMBER:** 26515427

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

------

**Issuer Free Writing Prospectus<br>Filed Pursuant to Rule 433<br>Registration Statement No. 333-289851<br>To Preliminary Prospectus Supplement dated January 6, 2026<br>(to Prospectus dated September 2, 2025)**

![](formfwpxu002.jpg)

------

![](formfwpxu003.jpg)

------

![](formfwpxu004.jpg)

------

![](formfwpxu005.jpg)

------

![](formfwpxu006.jpg)

------

![](formfwpxu007.jpg)

------

![](formfwpxu008.jpg)

------

![](formfwpxu009.jpg)

------

![](formfwpxu010.jpg)

------

![](formfwpxu011.jpg)

------

![](formfwpxu012.jpg)

------

![](formfwpxu013.jpg)

------

![](formfwpxu014.jpg)

------

![](formfwpxu015.jpg)

------

![](formfwpxu016.jpg)

------

![](formfwpxu017.jpg)

------

![](formfwpxu018.jpg)

------

![](formfwpxu019.jpg)

------

![](formfwpxu020.jpg)

------

![](formfwpxu021.jpg)

------

![](formfwpxu022.jpg)

------

![](formfwpxu023.jpg)

------

![](formfwpxu024.jpg)

------

![](formfwpxu025.jpg)

------

![](formfwpxu026.jpg)

------

![](formfwpxu027.jpg)

------

![](formfwpxu028.jpg)

------

![](formfwpxu029.jpg)

------

![](formfwpxu030.jpg)

------

![](formfwpxu031.jpg)

------

![](formfwpxu032.jpg)

------

![](formfwpxu033.jpg)

------

![](formfwpxu034.jpg)

------

![](formfwpxu035.jpg)

------

![](formfwpxu036.jpg)

------

**<u>Important Additional Information</u>**

Bright Minds Biosciences Inc. (the "**Issuer**") has filed a registration statement on Form F-3 (including a base prospectus (the "**Base Prospectus**")) with the U.S. Securities and Exchange Commission (the "**SEC**") (File No. 333-289851), and a preliminary prospectus supplement that incorporates the Base Prospectus (together, the "**Preliminary Prospectus**"), for the offering (the "**Offering**") to which this communication relates. The Issuer intends to file a further prospectus supplement (together with the base prospectus, the "**Prospectus**") for the Offering. Before you invest, you should read the Prospectus and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this Offering.

You may get these documents for free by visiting EDGAR on the SEC Web site at <u>www.sec.gov</u>. Alternatively, the Issuer, any underwriter or any dealer participating in the Offering will arrange to send you the Preliminary Prospectus and/or the Prospectus if you request it by calling the Issuer toll-free at +1-888-482-0763 or by emailing Alex Vasilkevich, Chief Operating Officer, at <u>alex@brightmindsbio.com</u>.

------